Shire Pharmaceuticals Ireland Limited (responsible for batch release) / Takeda Pharmaceuticals International AG Ireland Branch (responsible for batch release)
UkraineAll drugs from this manufacturer
-
The drug is intended for the long-term treatment of people with Hunter syndrome (mucopolysaccharidosis type II).
Dosage form: concentrate for infusion solution
Active substance Dosage idursulfase 2 mg/ml ATC: A16AB09
-
The drug is intended for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase deficiency).
Dosage form: concentrate for infusion solution
Active substance Dosage agalsidase alfa 1 mg/ml ATC: A16AB03
-
The drug is intended for long-term enzyme replacement therapy in patients with type I Gaucher disease.
Dosage form: powder for solution for infusion
Active substance Dosage velaglucerase alfa 400 IU ATC: A16AB10